-
Sichuan Biokin Launches Phase III Trial for Bispecific ADC BL-B01D1 in Lung Cancer
•
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a Phase III clinical trial for its proprietary bispecific antibody drug conjugate (ADC), BL-B01D1. This innovative therapy is being evaluated for the treatment of recurrent small-cell lung cancer (SCLC) in patients who have previously not responded…
-
Kelun Pharmaceutical’s Sacituzumab Tirumotecan Receives Priority Review for NSCLC Treatment
•
Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) has announced that its drug sacituzumab tirumotecan (SKB264/MK-2870) has been granted priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This designation is for the drug’s application as a treatment for locally advanced or metastatic…
-
Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer
•
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and Daiichi Sankyo (TYO: 4568), has received conditional approval in China for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) who have undergone two or more…
-
Mabwell’s Nectin-4 Targeting ADC 9MW2821 on Path to Breakthrough Designation in China for Urothelial Carcinoma
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced that its antibody drug conjugate (ADC), 9MW2821, which targets Nectin-4, is on track to receive breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the…
-
Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana
•
Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY) growth of 24.3%, with revenues reaching JPY 436.18 billion (USD 3.0 billion). This Q1’24 result is notable for being the first to not include revenues from Daiichi Sankyo Espha, the company’s generics unit that was…
-
Lepu Biotechnology’s MRG003 Earns FDA Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
•
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has announced that it has received Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA) for its pipeline candidate, MRG003. This designation highlights the drug’s potential in treating recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), a significant…
-
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
•
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen’s B7H3/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has…
-
NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS
•
The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) for the reimbursement of the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) within the National Health Service (NHS) have concluded without an agreement. Enhertu is approved in the…
-
Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak
•
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for the second quarter of 2024, showing a 3% year-on-year (YOY) increase in global revenues in constant currency terms, reaching USD 13.283 billion. This marks the first quarter of positive growth for Pfizer since the peak…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its innovative antibody drug conjugate (ADC), SHR-A1921. The study will evaluate the efficacy and safety of SHR-A1921…
-
Shanghai Escugen Partners with Innolake Biopharma to Develop Novel ADCs Using EZWi-Fit Platfo
•
Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm Innolake Biopharma to utilize Escugen’s innovative antibody-drug conjugate (ADC) platform, EZWi-Fit, in the development of ADC products targeting specific antigens selected by Innolake. Under the terms of the agreement, Innolake will employ EZWi-Fit to…
-
Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302
•
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG: 2186), has received approval from the National Medical Products Administration (NMPA) to commence a Phase I clinical trial for its proprietary antibody-drug conjugate (ADC), BA1302. The trial, which is multi-center, open-label, and involves multiple dosages…
-
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
•
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second quarter and the first half of 2024, demonstrating robust growth. For the six-month period, total revenues increased by 18% year-on-year (YOY) to $25.617 billion, with product sales also experiencing an 18% rise to $24.629 billion.…
-
Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation
•
Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent player in the global pharmaceutical industry. This collaboration aims to leverage Medicilon’s pre-clinical research and development expertise with Hengrui’s innovative drive and…
-
Shanghai Escugen and Sidewinder Therapeutics Form Strategic Alliance for ADC Development
•
Shanghai Escugen, a leading biopharmaceutical company specializing in antibody drug conjugates (ADCs), has announced a strategic partnership with US-based Sidewinder Therapeutics Inc. Under the agreement, Sidewinder has been granted a license to Escugen’s proprietary EZWi-Fit ADC platform, enabling the development of multiple ADC products. This collaboration signifies a significant step…
-
Mabwell Bioscience Lands Orphan Drug Status for B7-H3 Targeting ADC in Small Cell Lung Cancer
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has been granted Orphan Drug Designation (ODD) by the National Medical Products Administration (NMPA) for its antibody drug conjugate (ADC), 7MW3711. The drug targets B7-H3, a receptor overexpressed in various cancers, and is specifically indicated for the treatment of small cell lung cancer…
-
Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs
•
Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen’s proprietary RenLite platform. These antibodies will be utilized…
-
Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset
•
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and China, has entered into a lucrative licensing agreement with South Korea-based SK Biopharmaceuticals, granting the latter exclusive global rights to develop, manufacture, and commercialize the radiopharmaceutical FL-091. The deal is valued at USD 571.5 million…
-
BeiGene Receives NMPA Greenlight for BG-C9074 Clinical Trial in Advanced Solid Tumors
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National Medical Products Administration (NMPA) in China has approved its clinical filing for the Category 1 pipeline candidate BG-C9074. The antibody drug conjugate (ADC) is set to be initially assessed for the treatment of general advanced solid tumors, marking…
-
Mabwell Bioscience’s 9MW2821 Earns FDA Fast Track Designation for Triple Negative Breast Cancer
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced that it has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its investigational antibody-drug conjugate (ADC), 9MW2821. This candidate is designed to target Nectin-4 and is currently in development…
